AstraZeneca, Daiichi share data behind Dato-DXd do-over amid 2nd bid for lung cancer approval

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at the second attempt. The partners showed off subgroup overall survival data that exceeded the result seen in the broader population, providing evidence to support the pivot.